Your browser doesn't support javascript.
loading
Discovery of novel CSF biomarkers to predict progression in dementia using machine learning.
Gogishvili, Dea; Vromen, Eleonora M; Koppes-den Hertog, Sascha; Lemstra, Afina W; Pijnenburg, Yolande A L; Visser, Pieter Jelle; Tijms, Betty M; Del Campo, Marta; Abeln, Sanne; Teunissen, Charlotte E; Vermunt, Lisa.
Affiliation
  • Gogishvili D; Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. d.gogishvili@vu.nl.
  • Vromen EM; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
  • Koppes-den Hertog S; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Lemstra AW; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Pijnenburg YAL; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • Visser PJ; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
  • Tijms BM; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Del Campo M; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
  • Abeln S; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Teunissen CE; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
  • Vermunt L; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
Sci Rep ; 13(1): 6531, 2023 04 21.
Article in En | MEDLINE | ID: mdl-37085545
ABSTRACT
Providing an accurate prognosis for individual dementia patients remains a challenge since they greatly differ in rates of cognitive decline. In this study, we used machine learning techniques with the aim to identify cerebrospinal fluid (CSF) biomarkers that predict the rate of cognitive decline within dementia patients. First, longitudinal mini-mental state examination scores (MMSE) of 210 dementia patients were used to create fast and slow progression groups. Second, we trained random forest classifiers on CSF proteomic profiles and obtained a well-performing prediction model for the progression group (ROC-AUC = 0.82). As a third step, Shapley values and Gini feature importance measures were used to interpret the model performance and identify top biomarker candidates for predicting the rate of cognitive decline. Finally, we explored the potential for each of the 20 top candidates in internal sensitivity analyses. TNFRSF4 and TGF [Formula see text]-1 emerged as the top markers, being lower in fast-progressing patients compared to slow-progressing patients. Proteins of which a low concentration was associated with fast progression were enriched for cell signalling and immune response pathways. None of our top markers stood out as strong individual predictors of subsequent cognitive decline. This could be explained by small effect sizes per protein and biological heterogeneity among dementia patients. Taken together, this study presents a novel progression biomarker identification framework and protein leads for personalised prediction of cognitive decline in dementia.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2023 Document type: Article Affiliation country: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2023 Document type: Article Affiliation country: Países Bajos